Bucillamine - Santen Pharmaceutical

Drug Profile

Bucillamine - Santen Pharmaceutical

Alternative Names: Rimatil

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Class Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Japan (PO, Tablet)
  • 18 Jul 2007 Preclinical trials in Osteoarthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top